Trevor Phillips, executive chairman of Hvivo, said several companies had already expressed interest. Possible acquirers are those with established vaccines businesses, including GlaxoSmithKline. It is an exciting opportunity and we expect this asset to be worth a large sum of money.
Trevor Phillips, executive chairman of Hvivo, said several companies had already expressed interest. Possible acquirers are those with established vaccines businesses, including GlaxoSmithKline. It is an exciting opportunity and we expect this asset to be worth a large sum of money.